FYMCA Medical

FYMCA Medical is a Spanish biotechnology company headquartered in Granada, focused on developing innovative therapies for cancer treatment. The company specializes in the discovery and development of first-in-class small molecule inhibitors that target deoxycytidine kinase (dCK), an enzyme essential for DNA synthesis and repair in cancer cells. Their lead candidate, FYM-001, is designed to overcome resistance to conventional chemotherapies, particularly in aggressive solid tumors such as pancreatic and breast cancer. By modulating nucleotide metabolism, FYMCA's approach aims to enhance the efficacy of existing treatments and provide new options for patients with limited therapeutic alternatives. The company is currently advancing its pipeline through pre-clinical validation and is preparing for regulatory milestones to enter clinical trials.